Identification
- Generic Name
- Potassium cation
- DrugBank Accession Number
- DB01345
- Background
Potassium is the major cation (positive ion) inside animal cells, while sodium is the major cation outside animal cells. The concentration differences of these charged particles causes a difference in electric potential between the inside and outside of cells, known as the membrane potential. The balance between potassium and sodium is maintained by ion pumps in the cell membrane. The cell membrane potential created by potassium and sodium ions allows the cell generate an action potential—a "spike" of electrical discharge. The ability of cells to produce electrical discharge is critical for body functions such as neurotransmission, muscle contraction, and heart function. Potassium is also an essential mineral needed to regulate water balance, blood pressure and levels of acidity.
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Potassium cation (DB01345)
- Weight
- Average: 39.0983
Monoisotopic: 38.963706861 - Chemical Formula
- K
- Synonyms
- Potassium (ion)
- Potassium ion
- potassium(1+)
- potassium(1+) ion
- potassium(I) cation
Pharmacology
- Indication
Potassium is used to regulate hypokalemia as a primary condition or secondary to other medical conditions.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Therapies
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
Potassium is the major cation (positive ion) inside animal cells, while sodium is the major cation outside animal cells. The concentration differences of these charged particles causes a difference in electric potential between the inside and outside of cells, known as the membrane potential. The balance between potassium and sodium is maintained by ion pumps in the cell membrane. The cell membrane potential created by potassium and sodium ions allows the cell generate an action potential—a "spike" of electrical discharge. The ability of cells to produce electrical discharge is critical for body functions such as neurotransmission, muscle contraction, and heart function. Potassium is also an essential mineral needed to regulate water balance, blood pressure and levels of acidity.
Target Actions Organism USodium/potassium-transporting ATPase subunit alpha-1 Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Mostly urine but also skin and feces.
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Potassium cation may increase the excretion rate of Abacavir which could result in a lower serum level and potentially a reduction in efficacy. Acebutolol Potassium cation may increase the hyperkalemic activities of Acebutolol. Aceclofenac Potassium cation may increase the excretion rate of Aceclofenac which could result in a lower serum level and potentially a reduction in efficacy. Acemetacin The therapeutic efficacy of Potassium cation can be decreased when used in combination with Acemetacin. Acetaminophen Potassium cation may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy. Acetazolamide Acetazolamide may increase the excretion rate of Potassium cation which could result in a lower serum level and potentially a reduction in efficacy. Acetylsalicylic acid Acetylsalicylic acid may decrease the excretion rate of Potassium cation which could result in a higher serum level. Aclidinium Potassium cation may increase the excretion rate of Aclidinium which could result in a lower serum level and potentially a reduction in efficacy. Acrivastine Potassium cation may increase the excretion rate of Acrivastine which could result in a lower serum level and potentially a reduction in efficacy. Acyclovir Potassium cation may increase the excretion rate of Acyclovir which could result in a lower serum level and potentially a reduction in efficacy. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image POLİFLEKS LAKTATLI RİNGER IV İNFÜZYON İÇİN ÇÖZELTİ, 100 ML (PVC TORBA) SETLI Potassium cation (5.37 mEq/L) + Calcium cation (4 mEq/L) + Chloride ion (112 mEq/L) + Lactic acid (26.77 mEq/L) + Sodium cation (129.3 mEq/L) Solution Intravenous POLİFARMA İLAÇ SAN. VE TİC. A.Ş. 2020-08-14 Not applicable Turkey 
POLİFLEKS LAKTATLI RİNGER IV İNFÜZYON İÇİN ÇÖZELTİ, 100 ML (PVC TORBA) SETSİZ Potassium cation (5.37 mEq/L) + Calcium cation (4 mEq/L) + Chloride ion (112 mEq/L) + Lactic acid (26.77 mEq/L) + Sodium cation (129.3 mEq/L) Solution Intravenous POLİFARMA İLAÇ SAN. VE TİC. A.Ş. 2020-08-14 Not applicable Turkey POLİFLEKS LAKTATLI RİNGER IV İNFÜZYON İÇİN ÇÖZELTİ, 1000 CC SETLI Potassium cation (5.37 mEq/L) + Calcium cation (4 mEq/L) + Chloride ion (112 mEq/L) + Lactic acid (26.77 mEq/L) + Sodium cation (129.3 mEq/L) Solution Intravenous POLİFARMA İLAÇ SAN. VE TİC. A.Ş. 2020-08-14 Not applicable Turkey POLİFLEKS LAKTATLI RİNGER IV İNFÜZYON İÇİN ÇÖZELTİ, 1000 CC SETSİZ Potassium cation (5.37 mEq/L) + Calcium cation (4 mEq/L) + Chloride ion (112 mEq/L) + Lactic acid (26.77 mEq/L) + Sodium cation (129.3 mEq/L) Solution Intravenous POLİFARMA İLAÇ SAN. VE TİC. A.Ş. 2020-08-14 Not applicable Turkey POLİFLEKS LAKTATLI RİNGER IV İNFÜZYON İÇİN ÇÖZELTİ, 150 ML (PVC TORBA) SETLI Potassium cation (5.37 mEq/L) + Calcium cation (4 mEq/L) + Chloride ion (112 mEq/L) + Lactic acid (26.77 mEq/L) + Sodium cation (129.3 mEq/L) Solution Intravenous POLİFARMA İLAÇ SAN. VE TİC. A.Ş. 2020-08-14 Not applicable Turkey POLİFLEKS LAKTATLI RİNGER IV İNFÜZYON İÇİN ÇÖZELTİ, 150 ML (PVC TORBA) SETSİZ Potassium cation (5.37 mEq/L) + Calcium cation (4 mEq/L) + Chloride ion (112 mEq/L) + Lactic acid (26.77 mEq/L) + Sodium cation (129.3 mEq/L) Solution Intravenous POLİFARMA İLAÇ SAN. VE TİC. A.Ş. 2020-08-14 Not applicable Turkey POLİFLEKS LAKTATLI RİNGER IV İNFÜZYON İÇİN ÇÖZELTİ, 2000 ML (PVC TORBA) SETLI Potassium cation (5.37 mEq/L) + Calcium cation (4 mEq/L) + Chloride ion (112 mEq/L) + Lactic acid (26.77 mEq/L) + Sodium cation (129.3 mEq/L) Solution Intravenous POLİFARMA İLAÇ SAN. VE TİC. A.Ş. 2020-08-14 Not applicable Turkey POLİFLEKS LAKTATLI RİNGER IV İNFÜZYON İÇİN ÇÖZELTİ, 2000 ML (PVC TORBA) SETSİZ Potassium cation (5.37 mEq/L) + Calcium cation (4 mEq/L) + Chloride ion (112 mEq/L) + Lactic acid (26.77 mEq/L) + Sodium cation (129.3 mEq/L) Solution Intravenous POLİFARMA İLAÇ SAN. VE TİC. A.Ş. 2020-08-14 Not applicable Turkey POLİFLEKS LAKTATLI RİNGER IV İNFÜZYON İÇİN ÇÖZELTİ, 250 ML (PVC TORBA) SETLI Potassium cation (5.37 mEq/L) + Calcium cation (4 mEq/L) + Chloride ion (112 mEq/L) + Lactic acid (26.77 mEq/L) + Sodium cation (129.3 mEq/L) Solution Intravenous POLİFARMA İLAÇ SAN. VE TİC. A.Ş. 2020-08-14 Not applicable Turkey POLİFLEKS LAKTATLI RİNGER IV İNFÜZYON İÇİN ÇÖZELTİ, 250 ML (PVC TORBA) SETSİZ Potassium cation (5.37 mEq/L) + Calcium cation (4 mEq/L) + Chloride ion (112 mEq/L) + Lactic acid (26.77 mEq/L) + Sodium cation (129.3 mEq/L) Solution Intravenous POLİFARMA İLAÇ SAN. VE TİC. A.Ş. 2020-08-14 Not applicable Turkey - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Rurina Potassium cation (0.25 g/1L) + Chloride ion (0.11 g/1L) + Sulfate ion (3.6 g/1L) Liquid Topical TELOM-X GENE Co., Ltd. 2017-07-01 Not applicable US 
Rurina Potassium cation (0.25 g/1L) + Chloride ion (0.11 g/1L) + Sulfate ion (3.6 g/1L) Liquid Topical Nano Bio Tech Co.,Ltd 2017-07-01 Not applicable US Telom-X-gene Potassium cation (0.25 g/1L) + Chloride ion (0.11 g/1L) + Sulfate ion (3.6 g/1L) Liquid Topical TELOM-X GENE Co., Ltd. 2017-07-01 Not applicable US
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 295O53K152
- CAS number
- 24203-36-9
- InChI Key
- NPYPAHLBTDXSSS-UHFFFAOYSA-N
- InChI
- InChI=1S/K/q+1
- IUPAC Name
- potassium(1+) ion
- SMILES
- [K+]
References
- Synthesis Reference
John B. Sardisco, "Production of potassium sulfate and hydrogen chloride." U.S. Patent US4045543, issued 1865.
US4045543- General References
- Not Available
- External Links
- PDB Entries
- 1a3w / 1a3x / 1a49 / 1a5a / 1a5b / 1a9x / 1ad1 / 1ad4 / 1akd / 1aop … show 3770 more
- FDA label
- Download (632 KB)
- MSDS
- Download (139 KB)
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- American Regent
- Hospira Inc.
- Luitpold Pharmaceuticals Inc.
- Dosage Forms
Form Route Strength Injection, solution Intravenous Solution Intravenous Liquid Topical - Prices
- Not Available
- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US6946149 No 2005-09-20 2023-03-07 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 1067 °C (potassium sulfate) MSDS boiling point (°C) 1689 °C (potassium sulfate) MSDS water solubility 110 g/l (20°C) (potassium sulfate) MSDS - Predicted Properties
Property Value Source logP 0.2 Chemaxon pKa (Strongest Acidic) 3.09 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 0 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 0 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 0 m3·mol-1 Chemaxon Polarizability 1.78 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Steroid hormone binding
- Specific Function
- This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates th...
- Gene Name
- ATP1A1
- Uniprot ID
- P05023
- Uniprot Name
- Sodium/potassium-transporting ATPase subunit alpha-1
- Molecular Weight
- 112895.01 Da
References
- Silva E, Gomes P, Soares-da-Silva P: Overexpression of Na(+)/K (+)-ATPase parallels the increase in sodium transport and potassium recycling in an in vitro model of proximal tubule cellular ageing. J Membr Biol. 2006;212(3):163-75. Epub 2007 Feb 28. [Article]
- Li C, Geering K, Horisberger JD: The third sodium binding site of Na,K-ATPase is functionally linked to acidic pH-activated inward current. J Membr Biol. 2006;213(1):1-9. Epub 2007 Mar 8. [Article]
- Stanely Mainzen Prince P, Karthick M: Preventive effect of rutin on lipids, lipoproteins, and ATPases in normal and isoproterenol-induced myocardial infarction in rats. J Biochem Mol Toxicol. 2007;21(1):1-6. [Article]
- Simon WA, Herrmann M, Klein T, Shin JM, Huber R, Senn-Bilfinger J, Postius S: Soraprazan: setting new standards in inhibition of gastric acid secretion. J Pharmacol Exp Ther. 2007 Jun;321(3):866-74. Epub 2007 Mar 16. [Article]
- Iannello S, Milazzo P, Belfiore F: Animal and human tissue Na,K-ATPase in normal and insulin-resistant states: regulation, behaviour and interpretative hypothesis on NEFA effects. Obes Rev. 2007 May;8(3):231-51. [Article]
Drug created at June 30, 2007 18:13 / Updated at March 21, 2023 17:58